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pHLIP ICG for delineation 
of tumors and blood flow 
during fluorescence‑guided surgery
Troy Crawford1,5, Anna Moshnikova1,5, Sean Roles1, Dhammika Weerakkody1, 
Michael DuPont1, Lukas M. Carter2, John Shen3, Donald M. Engelman4, Jason S. Lewis2, 
Oleg A. Andreev1 & Yana K. Reshetnyak1*
Fluorescence imaging has seen enduring use in blood flow visualization and is now finding a new 
range of applications in image‑guided surgery. In this paper, we report a translational study of a new 
fluorescent agent for use in surgery, pHLIP ICG, where ICG (indocyanine green) is a surgical fluorescent 
dye used widely for imaging blood flow. We studied pHLIP ICG interaction with the cell membrane lipid 
bilayer, the pharmacology and toxicology in vitro and in vivo (mice and dogs), and the biodistribution 
and clearance of pHLIP ICG in mice. The pHLIP ICG tumor targeting and imaging efficacy studies were 
carried out in several murine and human mouse tumor models. Blood vessels were imaged in mice and 
pigs. Clinical Stryker imaging instruments for endoscopy and open surgery were used in the study. 
Intravenously administered pHLIP ICG exhibits a multi‑hour circulation half‑life, offering protracted 
delineation of vasculature. As it clears from the blood, pHLIP ICG targets tumors and tumor stroma, 
marking them for surgical removal. pHLIP ICG is non‑toxic, marks blood flow for hours after injection, 
and effectively delineates tumors for improved resection on the day after administration.
More than a decade ago, the first pH-Low Insertion Peptide (pHLIP) was introduced as an agent for targeting 
acidity at the surfaces of cellular membranes in vitro and in vivo1,2. The molecular mechanism of action of acidity 
targeting by peptides of the pHLIP family has been well-investigated and has been the subject of many publica-
tions (see  review3 and references within it). pHLIP is a water-soluble, moderately hydrophobic peptide containing 
several carboxyl groups in a sequence of hydrophobic and polar residues (Fig. 1a). The dielectric environment 
at a membrane shifts the pKa’s of these carboxyl groups toward higher pHs, and a moderately low local pH (pH 
5–7) promotes the protonation of Asp and Glu residues and the C-terminal, membrane-inserting end of pHLIP 
peptide. Protonation increases the peptide’s hydrophobicity and triggers its partition into a membrane, which is 
accompanied by a coil-helix transition to form a stable helix across the membrane (transmembrane helix). pHLIP 
peptides target tumors with high precision, since high cell surface acidity or low pH  (pHsurf) is a byproduct of the 
elevated glycolytic metabolism and of overactivated carbonic anhydrases (CAIX) at cancer and activated immune 
 cells4–7. A variety of imaging and therapeutic agents are successfully delivered to tumors by pHLIP peptides (see 
 review8 and references within it). pHLIP peptides tumor targeting has been demonstrated in human cancerous 
tissues and more than 20 different human and murine cancer models including transgenic breast, prostate, pan-
creatic and skin models. pHLIP peptides tumor uptake was correlated with tumor extracellular  pH9–11. pHLIP 
peptides tumor targeting has been shown to be enhanced in tumors that are further acidified by co-injection of 
 glucose12 or by overexpression of CAIX at the surface of HCT116 cancer  cells10. Alternatively, pHLIP peptides 
tumor targeting was shown to be reduced by alkalization of tumors in mice fed with bicarbonate drinking  water13. 
Micro-metastases near primary tumors and in distant organs were shown to be very well targeted by pHLIP 
 peptides12,14–16. In multiple studies, it has been found that non-protonatable (at low pH) pHLIP variants, where 
some or all Asp/Glu residues were replaced by Lys, did not target tumors and did not exhibit pH-dependent 
membrane insertion. pHLIP peptides distribution within tumors, cellular localization and correlation with a 
variety of markers have been intensively  investigated12,13,17,18.
Since pHLIP peptides offer a unique approach to the targeting of a spectrum of tumor subtypes, we were 
motivated to develop a fluorescent pHLIP candidate in order to improve the surgical resection of tumors guided 
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by fluorescence. After testing a variety of fluorescent dyes with pHLIP  peptides14, we chose a widely used clini-
cal fluorescent dye, indocyanine green (ICG). In addition to its long record of safety, ICG was chosen to couple 
to pHLIP peptide as a clinical imaging candidate for two main reasons: first, the fluorescence of pHLIP ICG is 
enhanced about 20 times when pHLIP tethers ICG to the membrane, as compared to the emission of pHLIP 
ICG in aqueous  solution19,20, thus reducing the probability of false positive signal and contrast-to-noise  ratio12. 
Second, many clinical instruments for imaging ICG fluorescence have already been developed and are clinically 
 available21, which streamlines pHLIP ICG’s clinical adoption. Here we present the results of the translational 
studies, including in vitro and in vivo efficacy, pharmacology and toxicology, that reveal important properties 
of a pHLIP agent and form the basis for the clinical trials that will soon be initiated.
Methods
All manufacturing procedures were completed in accordance with good laboratory practice (GLP) quality control 
specifications. pHLIP ICG was synthesized and the agent was produced by Iris Biotech, GmbH (Germany) in 
partnership with Chemical and Biopharmaceutical Laboratories (CBL) (Greece) and then further optimized by 
CordenPharma. GLP pHLIP ICG verification batch #1912127 was manufactured in Frankfurt by CordenPharma; 
the acceptance criteria are presented in Supplementary Table SI,1. Stability studies were completed with pHLIP 
ICG formulations in PBS and PBS containing 5% DMSO or 5% Ethanol (vol/vol). Biophysical studies were carried 
out using POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) liposomes as mimics of cell membrane 
bilayers. Cytotoxicity was completed on human mammary epithelial cells (HMEpC), which were acquired from 
Cell Applications, Inc. and were authenticated and stored according to supplier’s instructions. Hemolysis assays 
were carried out using single donor human whole blood purchased from Innovative Research, Inc. The pHLIP 
ICG enzyme binding assays were performed by Eurofins Panlabs, Inc. Murine animal studies were conducted 
at the University of Rhode Island (URI) according to the approved by URI Institution Animal Care and Use 
Committee (IACUC) animal protocol AN04-12-011. Animal studies in pigs were conducted at the Porcine 
Laboratory, Sutter Institute for Medical Research (SIMR) according to the approved by SIMR IACUC animal 
protocol STE.10.19 (Stryker Endoscopy Imaging and Instrumentation Studies). The studies complied with the 
principles and procedures outlined by the National Institutes of Health for the care and use of animals. Animal 
studies at the Memorial Sloan Kettering Cancer Center (MSK) Antitumor Assessment Core Facility and Charles 
River Labs were conducted in accordance with approved Study Protocols and in compliance with the Depart-
ment of Health and Human Services, Food and Drug Administration (FDA), United States Code of Federal 
Regulations, Title 21, Pad: 58: Good Laboratory Practice for Nonclinical Laboratory Studies and as accepted by 
Regulatory Authorities throughout the European Union (OECD Principles of Good Laboratory Practice), and 
other countries that are signatories to the OECD Mutual Acceptance of Data Agreement. Detailed descriptions 
of all methods are presented in the Supporting Information.
Results
pHLIP ICG synthesis and characterization. The 28-amino-acid pHLIP Var3 peptide with free N- and 
C-terminus was synthesized on solid support followed by purification and conjugation of its single Cys residue 
with ICG-maleimide to obtain the pHLIP ICG imaging agent (Fig. 1a, Supplementary Figure SI,1a). Further 
optimization of the pHLIP ICG manufacturing protocol has been completed by CordenPharma. pHLIP ICG 
reconstituted in PBS was found to be stable in solution for 4 days at room temperature.
The molar attenuation coefficient (i.e. extinction coefficient) of pHLIP ICG at 810 nm measured in methanol 
(Supplementary Figure SI,2a) was determined to be 153,000 M−1 cm−1 and was used to calculate the concentra-
tion of pHLIP ICG. The absorption and emission spectra of pHLIP ICG in DMF (to mimic the hydrophobic 
environment of the membrane) are shown in Fig. 1b. It is important to note that spectral signals of pHLIP ICG 
do not overlap with the absorption or emission of Methylene Blue and Isosulfan Blue, dyes which are widely used 
for lymph nodes staining during surgery (Supplementary Figure SI,2b–f). The interaction of pHLIP ICG with 
membrane lipid bilayers was studied using POPC liposomes. pHLIP ICG exhibits pHLIP-like pH-dependent 
interactions with cell membranes monitored by changes of the peptide circular dichroism and the fluorescence 
Figure 1.  Characterization of pHLIP ICG and blood clearance in mice and dogs. (a) The Var3 pHLIP sequence 
is shown with the chemical structure of the ICG dye coupled to a single Cys residue at the N-terminal part of 
pHLIP peptide. (b) Normalized absorbance (black line) and fluorescence (red line) spectra (the excitation is at 
805 nm) of pHLIP ICG (5 µM) measured in DMF. (c) Circular dichroism (CD) spectra of pHLIP ICG measured 
in phosphate buffer (pH 8) in absence (pHLIP ICG, pH 8—black line) and presence (pHLIP ICG + PC, pH 8—
blue line) of POPC liposomes, and in the presence of POPC liposomes at pH 5.2 (pHLIP ICG + PC, pH 5.2—red 
line) indicate on formation of helical structure in membrane at low pH. (d) pH-dependent insertion of pHLIP 
ICG into the bilayers of POPC liposomes monitored by changes of the CD spectral signal at 222 nm. The data 
were fitted with the Henderson-Hasselbach equation (red line with 95% confidence interval) to establish the 
midpoint of the transition (pK). (e) The kinetics signal (multiplied by − 1) of pHLIP ICG insertion into lipid 
bilayers of POPC liposomes as a result of a pH drop from pH 8 (blue line in insert) to pH 5 (red line in insert) 
was monitored in real-time by the tryptophan fluorescence changes (black line). The gray line is a baseline 
obtained by mixing pHLIP ICG with POPC liposomes at pH 8 with pH 8 buffer. The red line is a bi-exponential 
fit of the experimental data (85% of the signal changes occur with a rate of 5 s−1 and about 15% of final 
adjustment is completed at a rate of 0.077 s−1). (f,g) Blood clearance profile and single exponential fitting curves 
(red lines) obtained from mice (f) and dogs (g) after a single i.v. injection of 12.3 mg/kg of pHLIP ICG to mice 
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emission of tryptophan residues (Fig. 1c–e). pHLIP ICG is inserted into lipid bilayer of membrane and forms 
alpha helical structure at low pHs, as do all peptides of pHLIP  family3,22. The midpoint of the transition for pHLIP 
ICG insertion in liposomes is at pH 6.3 as calculated from graph presented on Fig. 1d. Thus, at pH 6.0 (below of 
midpoint), pH which is found at the surface of cancer cells within  tumors23,24, about 70% of pHLIP ICG molecules 
are expected to be inserted across plasma membrane at equilibrium, while at pH 7.4 (the surface pH of normal 
cells) < 1% of pHLIP ICG molecules are expected to be inserted into the membranes. Since the rate constant of 
pHLIP ICG insertion into a membrane is high (approximately 5 s−1), the insertion will occur even under condi-
tions of fast blood flow and limited exposure time of pHLIP ICG to acidic cancer cells.
Safety studies in vitro. Safety pharmacology profiling of pHLIP ICG (2 µM) was performed in vitro using 
86 enzyme and receptor targets. No inhibitory effect was observed, except a mild inhibitory effect of pHLIP ICG 
on progesterone receptor B: the established IC50 and Ki for pHLIP ICG are 0.64 µM and 0.51 µM, respectively 
(for comparison, the IC50 and Ki  for the known R-2050 progesterone receptor agonist are several-fold lower: 
0.33 nM and 0.26 nM, respectively; Supplementary Figure SI,3). It is unlikely that a significant amount of pHLIP 
ICG would reach the nucleus after a single i.v. administration of the agent, since it binds to cellular membranes.
The cytotoxicity of pHLIP ICG was assessed by treatment of human mammary epithelial cells (HMEpC) with 
increasing concentrations of pHLIP ICG (up to 16 µM) for 72 h, followed by assessment of cell viability. pHLIP 
ICG did not show any cytotoxic effect at any tested concentration.
Hemolysis assays were performed on single donor human whole blood samples treated with increasing 
concentrations (up to 8 nmol/mL) of pHLIP ICG. Hemolysis was assessed by the release of hemoglobin into the 
supernatant as monitored by measuring absorbance at 450 nm after centrifugation to remove red blood cells 
(RBC). The amount of RBC lysis was less than 2% in all samples compared to 100% release upon lysis by water 
or Triton X-100.
The genotoxicity of pHLIP ICG was evaluated using in vitro bacterial reverse mutation and mammalian cell 
micronucleus tests in human peripheral blood lymphocytes (see details in Supplementary Information). pHLIP 
ICG did not show any evidence of genotoxic activity in these in vitro mutagenicity assays.
Pharmacology. Pharmacokinetic studies were performed in mice and dogs. Blood samples were collected 
at 5, 15, 30 min and 1, 2, 4, 6, 8, 12 or 16, 24 and 48 h after a single i.v. dose of pHLIP ICG (12.3 mg/kg to 
mice and 0.064 mg/kg to dogs). Evidence of systemic exposure to pHLIP ICG was observed in all animals and 
was quantifiable up to 8–16 h post administration (Supplementary Table SI,2). Single exponential decays were 
observed in both cases (Fig. 1f,g). The mean clearance (Cl), volume of distribution (Vz) and elimination half-
time (T1/2) values obtained for mice and dogs were very similar: Cl = 9.53 mL/h/kg (mice) and 11.6 mL/h/kg 
(dogs); Vz = 53.51 mL/kg (mice) and 61.6 mL/kg (dogs); and T1/2 = 3.9 h (mice) and 3.7 h (dogs).
Blood vessel imaging. Our pharmacology data show that pHLIP ICG remains at significant levels in the 
blood for several hours—an essential feature of good blood pool agents for fluorescence angiography. ICG, when 
used as a contrast agent for imaging blood flow, is cleared from the blood within a few minutes, limiting the time 
window for imaging. We carried out a comparative study of blood flow imaging in mice using ICG-Cys (ICG-
maleimide conjugated with a Cys residue) and pHLIP ICG (2.5 nmol of each). As expected, ICG-Cys was cleared 
from the blood within the first 5 min (Fig. 2a), whereas pHLIP ICG clearly revealed the blood vessels for up to 
2 h (Fig. 2b and Supplementary Figure SI,4). To further investigate the potential utility of pHLIP ICG in fluores-
cence angiography, blood perfusion was imaged in pigs, since the blood circulation of pigs is closely related to 
that of humans. Pigs received several doses of pHLIP ICG: 0.052 mg/kg (dose 1) followed by additional 0.12 mg/
kg (dose 2) and then an additional 0.24 mg/kg (dose 3). Visualization of pHLIP ICG NIR fluorescence in blood 
vessels was performed using two systems: (i) for endoscopic/laparoscopic imaging inside the pig body cavity 
(Fig. 3a, Supplementary Figure SI,5a and Supplementary Video SI,1), and (ii) open-field imaging of a pedicle flap 
(Fig. 3b, Supplementary Figure SI,5b and Supplementary Video SI,2). Illuminated blood vessels were clearly vis-
ible at 2 h post-injection (Supplementary Figure SI,5), establishing the superiority of pHLIP ICG use over ICG 
in fluorescence angiography and other blood flow/perfusion applications, when prolonged imaging is required.
Biodistribution and tumor targeting. Biodistribution and tumor targeting were assessed after a single 
tail vein injection of pHLIP ICG in mice bearing murine and human tumors. Biodistribution studies were car-
ried out in female and male mice bearing a triple-negative 4T1 tumor, which closely mimics stage IV human 
breast cancer. Targeting of 4T1 tumors in BALB/c mice by pHLIP ICG is shown in Supplementary Figure SI,6. 
To establish the biodistribution of pHLIP ICG, animals were euthanized at different time points (5 min, 1, 2, 4, 
6, 16, 26 and 48 h) and organs were collected and imaged. Representative images of organs are shown in Sup-
plementary Figure SI,7; values of fluorescence intensity are shown in Supplementary Table SI,3 and mean values 
are given in Supplementary Table SI,4; the calculated signal level in each organ at different time points is shown 
in Supplementary Figure SI,8. The kinetics of the fluorescence signal changes in organs and tissue is shown in 
Fig. 4. Organs and tissues were frozen after imaging and processed to measure the signal in the tissue/organ 
homogenates. The measurement precision of the amount of fluorescent compound in the tissues and organs 
is limited, but estimates are possible. The estimations were made from a calibration curve obtained by spiking 
known amounts of pHLIP ICG with organs and tissue homogenates collected from control animals. According 
to our estimates, the amount of pHLIP ICG within the tumor reaches about 10–15% ID/g at 4 h post injec-
tion and stays constant up to 24 h, decaying slightly at 48 h. The clearance was observed to be predominantly 
hepatic, and the level of the signal increases in the liver with time and reaches a maximum level at 1-h post-
administration, followed by signal decay after 6 h. Well-perfused organs like the heart, kidney and lungs were 
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imaged (no perfusion with buffer); it is evident that a significant amount of the signal (especially at earlier time 
points) comes from the blood associated with these organs, and that the signal level decays with blood clearance. 
Another group of organs, including the spleen, pancreas, stomach and brain, has a lower signal level, which also 
decays with blood clearance. Small and large intestines, bone, skin and muscle (and prostate in male animals, not 
shown here) have very low signal levels, estimated to be less than 2% ID/g at all time points. At 20–48 h, when 
the blood has cleared and the fluorescence signal in all organs is minimal, the contrast between the tumor and 
the surrounding tissue or healthy organs is significant.
pHLIP ICG tumor targeting was observed in several breast tumor models (MDA-MB-231 human and 4T1 
murine, each is triple-negative), lung (A549 human and LLC murine), epithelial (melanoma) (M4A4 human), 
cervical (HeLa human), urinary bladder (UM-UC3 human) and prostate (LNCaP human) cancers. NIR fluores-
cence imaging on live animals using the Stryker clinical imaging system was performed at 24 h after a single i.v. 
administration of pHLIP ICG (Supplementary Figure SI,9). To closely mimic the conditions of intraoperative 
imaging, during which fluorescence is monitored from exposed tissue, the skin was removed from the tumor 
side while animals were under anesthesia. Excellent tumor targeting by pHLIP ICG was seen, as was a clear 
visualization of small, medium and large tumors positioned deep in the tissue or exposed at the surface, includ-
ing small nearby micro-metastases (representative images are shown in Fig. 5). MDA-MB231 breast tumor cells 
were injected in the area of the mammary fat pads of athymic nude mice, and, most probably, drained into the 
Figure 2.  Imaging of blood vessels in mice. Representative NIR pHLIP ICG fluorescent images of blood vessels 
at different time points after a single i.v. injection of ICG-Cys (a) or pHLIP ICG (b).
6
Vol:.(1234567890)
Scientific Reports |        (2020) 10:18356  | https://doi.org/10.1038/s41598-020-75443-5
www.nature.com/scientificreports/
inguinal lymph nodes (LN). Both the primary tumor site and the LN were targeted by pHLIP ICG (Figs. 5a, 6a). 
Previous studies show no targeting of inguinal LNs by a pHLIP  peptide25, so the observed targeting is likely to 
be reporting cancerous LNs. Removal of the tumor and imaging of the tumor bed is shown in Supplementary 
Figure SI,10. To further examine the contrast between tumor and normal tissue, the tumors were removed with 
surrounding muscle tissue (Fig. 6). The border between tumor and muscle in most cases was evidently visible 
and was defined with high precision by the fluorescence signal. To correlate the pHLIP ICG NIRF signal with 
tumor location, the tumor-muscle pieces were frozen immediately following NIRF imaging, sectioned, fixed 
and stained with hematoxylin and eosin (HE). An excellent correlation between pHLIP ICG imaging and HE 
histopathology in locating the tumors is shown in Fig. 7. Fluorescent (unprocessed) and HE-stained sections 
were examined via an IR scanner and optical microscope. Tumors (marked as T) and surrounding tumor stroma 
(marked as TS1, TS2 and TS3) exhibit pHLIP ICG NIR fluorescent signal, as opposed to the muscles (marked as 
M1 and M2). Cancer cells infiltrating surrounding muscles are clearly seen in magnified images of tumor stroma, 
in agreement with previous  findings13. The ability of pHLIP ICG to stain both tumor mass and tumor stroma is 
expected to improve margin resection during surgery.
Fluorescence‑guided resection of tumors. To establish the optimal concentration and timing after 
pHLIP ICG administration, surgical resection of the implanted tumors was performed at 24 and 48  h after 
pHLIP ICG tail vein injection at doses ranging from 0.5 to 2.5 mg/kg. The minimal dose of 0.5 mg/kg was suf-
ficient for the successful visualization of tumors using a Stryker SPY-PHI handheld clinical instrument, which 
will be used in breast cancer surgical clinical trials for imaging of pHLIP ICG. The images and video obtained 
during the procedure are presented in Supplementary Figure SI,11 and Supplementary Video SI,3.
Figure 3.  Imaging of blood vessels in pigs. Representative NIR pHLIP ICG (verification batch #1912127) 
fluorescent images and overlay of fluorescent and color images of blood vessels at different time points after 
injection of pHLIP ICG in PBS (dose 1—0.052 mg/kg; dose 2—additional 0.12 mg/kg; dose 3—additional 
0.24 mg/kg) are shown. (a) Imaging inside the pig body cavity was performed using a Stryker 1688 AIM 
system (808 nm excitation) for endoscopic/laparoscopic imaging (gain 8/10 for dose 2, gain 7/10 for dose 3). 




Scientific Reports |        (2020) 10:18356  | https://doi.org/10.1038/s41598-020-75443-5
www.nature.com/scientificreports/
GLP safety animal studies. The animal efficacy studies indicated that satisfactory imaging can be attained 
with a dose of 0.5 mg/kg of pHLIP ICG, which corresponds to a 0.04 mg/kg human dose (h.d.) per Body Surface 
Area (BSA)26. Various toxicology studies were performed on mice, dogs, rats and rabbits at doses of 25 × to 30 × 
the h.d., the maximum feasible dose (the details of these studies can be found in the Section “Pharmacology and 
Toxicology Studies” in the Supplementary Information). In summary, the following GLP studies were carried 
out with no adverse effects being observed, supporting the safety of translation of the agent to human trials:
Figure 4.  Kinetics. The calculated mean and standard deviation values at different time points post-dose are 
shown. Values are given in Supplementary Table SI,5. The description of %ID/g calculations is presented in the 
main text and “Methods” section.
8
Vol:.(1234567890)
Scientific Reports |        (2020) 10:18356  | https://doi.org/10.1038/s41598-020-75443-5
www.nature.com/scientificreports/
Single‑dose and 7‑days repeat i.v. toxicity in beagle dogs. pHLIP ICG was administered by single i.v. bolus 
injection at increasing doses such as 0.063 mg/kg (0.88 × h.d. recalculated for dog dose), 1.08 mg/kg (15 × h.d.), 
2.16 mg/kg (30 × h.d.) or once daily for 7 days at 2.16 mg/kg/day (30 × h.d. per day) to dogs, and did not adversely 
affect the overall health or condition of the animals, any of the measured clinical pathology parameters, organ 
weights, macroscopic or microscopic pathology. Based on these results, the no-observed-adverse-effect level 
(NOAEL) was above 2.16 mg/kg/day (30 × h.d. per day) for 7 days repeated administration of pHLIP ICG in 
males and females.
7‑day repeat i.v. toxicity in B6D2F1 mice. pHLIP ICG was administered once daily for 7 days at 4.92 mg/kg/day 
(10 × h.d. per day recalculated for mice dose), 7.38 mg/kg/day (15 × h.d. per day) and 12.3 mg/kg/day (25 × h.d. 
Figure 5.  Tumor targeting. Representative photos and overlay of photos and in vivo NIR pHLIP ICG 
fluorescent images of athymic female nude mice bearing murine and human tumors are shown with skin 
removed from the tumor site. Targeting of human breast MDA-MB-231 tumor (a), murine breast 4T1 tumor 
(b), human A549 lung tumor (c), murine LLC Lewis lung carcinoma (d), human M4A4 epithelial tumor (e), 
human HeLa cervical tumor (f), human UMUC3 urinary bladder tumor (g) and human prostate LNCaP tumor 
(h) are shown. The imaging was performed at 24 h after a single i.v. administration of pHLIP ICG. Arrows 
indicate tumor locations. In the case of the MDA-MB231 breast tumor model, both a small tumor (arrow at the 
right) and an inguinal lymph node (indicated as LN) are targeted.
9
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per day). The NOAEL was above 12.3 mg/kg/day (25 × h.d. per day) for 7 days repeated administration of pHLIP 
ICG in male and female mice.
A cardiovascular telemetry study in unrestrained, conscious non‑naïve beagle dogs. A single administration of 
pHLIP ICG at dose levels of 0.072 mg/kg (1 × h.d. recalculated for dog dose per BSA), 0.36 mg/kg (5 × h.d.), and 
1.44 mg/kg (20 × h.d.) to male dogs registered no effect on systemic blood pressures, heart rate, body tempera-
ture, electrocardiographic intervals, or qualitative ECG parameters up to 24 h post-dose.
Local tolerance/irritancy in New Zealand white rabbits. A single administration of pHLIP ICG at dose levels 
of 0.124 mg/kg (1 × h.d. recalculated for rabbit dose per BSA) and 1.86 mg/kg (15 × h.d.) through all routes of 
administration was well-tolerated and did not result in any pHLIP ICG-related changes.
Figure 6.  Ex vivo imaging of tumors with surrounding muscle. Representative photos, and overlays of photos 
and ex vivo NIR pHLIP ICG fluorescent images of tumors resected with surrounding tissue immediately after 
in vivo imaging. Targeting of human breast MDA-MB-231 tumor (a), murine breast 4T1 tumor (b), human 
A549 lung tumor (c), murine LLC Lewis lung carcinoma (d), human M4A4 epithelial tumor (e), human HeLa 
cervical tumor (f), human UMUC3 urinary bladder tumor (g) and human prostate LNCaP tumor (h) are 
shown. In the case of the MDA-MB231 breast tumor model, both a small tumor and an inguinal lymph node 
(indicated as LN) are targeted.
10
Vol:.(1234567890)
Scientific Reports |        (2020) 10:18356  | https://doi.org/10.1038/s41598-020-75443-5
www.nature.com/scientificreports/
A pharmacological safety assessment on the central nervous system in Sprague Dawley rats. A single adminis-
tration of pHLIP ICG at dose levels of 0.218 mg/kg (0.88 × h.d. recalculated for rat dose per BSA), 0.248 mg/kg 
(1 × h.d.), 3.72 mg/kg (15 × h.d.) and 7.44 mg/kg (30 × h.d.) had no effect on the central nervous system up to 
24 h post-dose.
Figure 7.  Ex vivo imaging and imaging of sections. (a) Representative images of tumors with surrounding 
tissue: photos, NIR pHLIP ICG fluorescent images, overlay of photos with NIR pHLIP ICG fluorescent images, 
and images of HE-stained sections obtained from the same tumor-muscle pieces are shown. (b) Bright field 
image of HE-stained section and NIR pHLIP ICG fluorescent images of the adjacent non-processed section 
obtained on IR scanner shown in monochrome (green) and 16-color (white and red are the highest intensity, 
and black and dark blue are the lowest intensity) presentations. T indicates tumor; M indicates muscle, and S 
indicates stroma. (c) Magnified bright field images (using 20 × objective) of tumor (T), muscle (M1 and M2), 
tumor stroma (TS1, TS2 and TS3) of HE-stained section are presented in panel (b).
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Micronucleus test in Sprague Dawley rats. A single administration of pHLIP ICG at dose levels of 6.25 mg/kg 
(25 × h.d. recalculated for rat dose per BSA), 12.5 mg/kg (50 × h.d.) and 25 mg/kg (100 × h.d.) showed no evi-
dence of genotoxic activity.
Discussion
Fluorescence imaging, which has long been used to image blood flow, is finding a new range of applications in 
image-guided surgery. For decades, fluorescence angiography has been applied to assess blood flow and tissue 
perfusion in preoperative, intraoperative and postoperative  settings27–31. Emerging uses in fluorescence-guided 
surgery promise to improve surgical outcomes by revealing tumor margins and, even more importantly, by mark-
ing flat lesions and micro-metastases adjacent to primary tumors, which are difficult to  identify32–35.
Several FDA-approved fluorescent dyes and compounds are now in clinical use. The most widely used is 
the near-infrared emitting ICG, first approved for angiography and subsequently used in ophthalmology and 
elsewhere for imaging blood  vessels36–41. ICG circulates in blood for a few minutes (2.5 min half-life)42,43 and is 
cleared through the liver, appearing in the bile about 8 min after  injection37. If administered intraperitoneally, 
ICG is found in the nearest lymph nodes within 15 min, and in the regional lymph nodes within 1–2 h44,45. The 
IV dose of ICG varies from 0.5 to 2.0 mg/mL/kg of body weight. At a high dose of 5 mg/kg, no acute toxicity has 
been  observed37 and chronic toxicity has not been reported over decades of many clinical uses of ICG.
Notwithstanding the utility that fluorescence-guidance using ICG has afforded to surgical procedures, there 
remain several important limitations associated with its use. ICG (as any non-targeted small molecule) does 
not strongly accumulate in tumors except for a very weak signal from enhanced permeation retention (EPR) in 
vascularized tumors. ICG may be taken up by some cancerous lesions only if blood flow uptake is enhanced for 
the particular lesion. In other cases, ICG has been used to visualize a lesion via a lack of signal, where the uptake/
signal of ICG was much lower within the lesion compared to the surrounding  tissue46. However, ICG does not 
have any inherent tumor-targeting properties based on selective binding. Also, the use of ICG for steady-state 
blood vessels visualization is limited by its very fast blood clearance profile, which can necessitate multiple injec-
tions in a single surgical procedure. pHLIP ICG resolves these deficiencies.
Tumor targeting by pHLIP peptides has been well-documented in a large variety of animal tumor models 
and human tissues. pHLIP ICG was used to image cancerous lesions in human  bladders19 and the human upper 
urinary  tract47. The agent was applied ex vivo after the surgical removal of organs, followed by washing and NIR 
fluorescent imaging using clinical imaging instruments. Malignant bladder lesions were targeted by pHLIP 
ICG and identified by NIR imaging; pathology showed a sensitivity of 97% and specificity of 100%. Carcinoma 
in situ was accurately diagnosed in 11 cases, whereas only four of these cases were seen using white light. All 
malignant upper tract lesions were targeted by pHLIP ICG and visualized on NIR imaging with a sensitivity of 
100% (compared to 78.9% white light imaging) and a specificity of 100%. Benign collecting systems and ureters 
did not show uptake of the pHLIP construct.
Taken together, the published work on the mechanism of pHLIP peptides action, on tumor targeting and 
visualization, as well as in the preclinical studies with pHLIP ICG presented here, including pharmacology 
and toxicology assessments, motivate the clinical translation of pHLIP ICG for systemic administration for (i) 
real-time blood vessels visualization and (ii) targeting and identification of cancerous lesions during surgical 
procedures. Further, real-time blood vessels imaging with pHLIP ICG is expected to significantly extend the 
imaging time window from several minutes to several hours, allowing imaging to be performed at any time dur-
ing a surgical procedure after a single injection of the agent. Potentially, multi-color imaging could be developed: 
pHLIP ICG could be used to visualize blood vessels, and pHLIP peptides with a fluorescent dye emitting in the 
range of 600–700 nm could be used for tumor imaging, allowing for the imaging of cancerous lesions and blood 
vessels during the same surgical procedure. It is expected that pHLIP ICG will allow accurate identification 
of tumor margins by staining of tumor mass and tumor stroma, targeting and visualization of flat lesions and, 
potentially, identification of micro-metastasis nearby primary tumor masses.
pHLIP ICG currently is in clinical translation for the fluorescence-guided surgical resection of breast tumors. 
According to the American Cancer Society, ~ 276,480 and ~ 48,530 new cases of invasive and non-invasive breast 
cancer will be diagnosed in US in 2020, and ~ 42,170 women will die from breast cancer. Surgery remains a 
dominant first approach to treatment, and there has been a significant shift in surgical practice toward breast-
conserving surgery since 1980. The goal is to remove the tumor mass and, at the same time, preserve as much 
healthy tissue as possible. Unfortunately, ~ 25% of patients with invasive carcinoma and one-third of those with 
ductal carcinoma in situ require re-excision with about half of the re-excisions done in patients with negative 
margins, defined as “no ink on tumor”48,49. Two factors are known to have an important role: the process of 
identification of tumor negative margins and breast cancer biology. The tumor margin is first established intra-
operatively (by eye), marked by ink, the tumor is resected, and, later, the “no ink on tumor margin” is confirmed 
by a pathologist. Difficulties in the marking of margins, specimen handling and pathology evaluation remain 
limitations to be  overcome50–52. Pathology assessment takes time and the margin status is known only after 
surgery. Even when the margin is negative (as accurately as can be established), the local recurrence is still high, 
especially in the cases of triple-negative breast cancer, which test negative for estrogen receptor (ER), progester-
one receptor (PR) and hormone epidermal growth factor receptor 2 (HER2), significantly limiting targeting and 
evaluations of this tumor type. In our study, we show targeting of triple-negative breast cancer in murine 4T1 
and human MDA-MB-231 mouse models, including targeting of cancerous LNs. If our findings are successfully 
translated to the clinic, significant improvements of surgical outcomes should be expected.
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